Amalgamated Bank grew its stake in shares of bluebird bio Inc (NASDAQ:BLUE) by 15.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,601 shares of the biotechnology company’s stock after buying an additional 866 shares during the period. Amalgamated Bank’s holdings in bluebird bio were worth $1,176,000 at the end of the most recent reporting period.
A number of other institutional investors also recently added to or reduced their stakes in BLUE. Ark Investment Management LLC increased its position in bluebird bio by 44.8% during the second quarter. Ark Investment Management LLC now owns 119,683 shares of the biotechnology company’s stock worth $12,573,000 after buying an additional 37,021 shares in the last quarter. Dimensional Fund Advisors LP increased its position in bluebird bio by 25.0% during the second quarter. Dimensional Fund Advisors LP now owns 106,189 shares of the biotechnology company’s stock worth $11,158,000 after buying an additional 21,228 shares in the last quarter. Raymond James Financial Services Advisors Inc. purchased a new position in bluebird bio during the second quarter worth $211,000. First Trust Advisors LP increased its position in bluebird bio by 46.9% during the third quarter. First Trust Advisors LP now owns 33,043 shares of the biotechnology company’s stock worth $4,538,000 after buying an additional 10,552 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System increased its position in bluebird bio by 7.4% during the third quarter. State Board of Administration of Florida Retirement System now owns 24,670 shares of the biotechnology company’s stock worth $3,388,000 after buying an additional 1,690 shares in the last quarter.
Several equities research analysts have recently issued reports on the company. Cantor Fitzgerald decreased their price objective on bluebird bio from $122.00 to $113.00 and set an “underweight” rating on the stock in a report on Thursday, February 22nd. William Blair assumed coverage on bluebird bio in a report on Monday, March 5th. They set an “outperform” rating and a $242.00 price objective on the stock. Morgan Stanley restated an “equal weight” rating and set a $152.00 price objective (up previously from $151.00) on shares of bluebird bio in a report on Monday, February 26th. Barclays restated an “overweight” rating and set a $209.00 price objective (up previously from $162.00) on shares of bluebird bio in a report on Wednesday, December 13th. Finally, Jefferies Group upgraded bluebird bio from a “hold” rating to a “buy” rating and raised their price objective for the stock from $130.00 to $211.00 in a report on Monday, December 11th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $187.60.
bluebird bio Inc (NASDAQ:BLUE) opened at $233.05 on Tuesday. bluebird bio Inc has a fifty-two week low of $74.45 and a fifty-two week high of $234.90. The firm has a market capitalization of $11,650.00, a price-to-earnings ratio of -43.32 and a beta of 2.05.
bluebird bio (NASDAQ:BLUE) last issued its earnings results on Wednesday, February 21st. The biotechnology company reported ($2.52) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.68) by ($0.84). bluebird bio had a negative net margin of 947.42% and a negative return on equity of 28.09%. The firm had revenue of $4.17 million during the quarter, compared to analyst estimates of $7.11 million. During the same quarter in the previous year, the business posted ($1.88) EPS. bluebird bio’s revenue was up 169.0% compared to the same quarter last year. research analysts expect that bluebird bio Inc will post -8.25 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/03/13/amalgamated-bank-buys-866-shares-of-bluebird-bio-inc-blue.html.
bluebird bio Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.